US4361549A
(en)
|
1979-04-26 |
1982-11-30 |
Ortho Pharmaceutical Corporation |
Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
|
US6893625B1
(en)
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
JP3095168B2
(ja)
|
1988-02-05 |
2000-10-03 |
エル. モリソン,シェリー |
ドメイン‐変性不変部を有する抗体
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
DK0826696T3
(da)
|
1996-09-03 |
2002-09-23 |
Gsf Forschungszentrum Umwelt |
Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
|
EP1060194A1
(en)
|
1998-02-25 |
2000-12-20 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
AU761587B2
(en)
|
1998-04-21 |
2003-06-05 |
Amgen Research (Munich) Gmbh |
CD19xCD3 specific polypeptides and uses thereof
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
CN100531798C
(zh)
|
1998-08-11 |
2009-08-26 |
拜奥根Idec公司 |
包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
EP2264166B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
MXPA01011279A
(es)
|
1999-05-07 |
2002-07-02 |
Genentech Inc |
Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
ITMI991299A1
(it)
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
US7396917B2
(en)
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
EP1395605B8
(en)
|
2001-03-09 |
2014-12-17 |
Iterative Therapeutics, Inc. |
Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors
|
CA2461631A1
(en)
|
2001-09-28 |
2003-04-03 |
Elusys Therapeutics, Inc. |
Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
AU2003208415B2
(en)
|
2002-02-14 |
2009-05-28 |
Immunomedics, Inc. |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8673589B2
(en)
|
2002-05-29 |
2014-03-18 |
Regeneron Pharmaceuticals, Inc. |
Inducible eukaryotic expression system
|
EP1400534B1
(en)
|
2002-09-10 |
2015-10-28 |
Affimed GmbH |
Human CD3-specific antibody with immunosuppressive properties
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
NZ581541A
(en)
|
2002-10-17 |
2011-07-29 |
Genmab As |
Human monoclonal antibodies against CD20
|
US7608260B2
(en)
|
2003-01-06 |
2009-10-27 |
Medimmune, Llc |
Stabilized immunoglobulins
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
EP1626993B1
(en)
|
2003-05-09 |
2015-03-11 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
JP2007501021A
(ja)
|
2003-05-30 |
2007-01-25 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
遺伝子操作された定常領域を含む、抗体および融合タンパク質
|
ATE455127T1
(de)
|
2003-05-31 |
2010-01-15 |
Micromet Ag |
Humane anti-humane cd3-bindungsmoleküle
|
EP1629013B1
(en)
|
2003-05-31 |
2018-01-24 |
Amgen Research (Munich) GmbH |
Pharmaceutical composition comprising a bispecific antibody specific for epcam
|
US20050163782A1
(en)
|
2003-06-27 |
2005-07-28 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
MXPA06002134A
(es)
|
2003-08-29 |
2006-05-31 |
Genentech Inc |
Terapia de trastornos oculares.
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
DE602004030811D1
(de)
|
2003-10-16 |
2011-02-10 |
Micromet Ag |
Multispezifische deimmunisierte cd3-bindende moleküle
|
EP1697419A2
(en)
|
2003-12-19 |
2006-09-06 |
Genentech Inc. |
Detection of cd20 in transplant rejection
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
CA2885854C
(en)
|
2004-04-13 |
2017-02-21 |
F. Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
BRPI0510224A
(pt)
|
2004-05-05 |
2007-10-23 |
Genentech Inc |
métodos de prevenção de doença autoimunológica e artigo industrializado
|
DK1753783T3
(en)
|
2004-06-03 |
2014-11-17 |
Novlmmune Sa |
Anti-CD3 antibodies, and methods of use thereof
|
BRPI0510885A
(pt)
|
2004-06-04 |
2007-12-26 |
Genentech Inc |
método de tratamento de lúpus e artigo industrializado
|
EP1812060A2
(en)
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
US20120189643A1
(en)
|
2004-11-30 |
2012-07-26 |
Carton Jill M |
Toll Like Receptor 3 Antagonists, Methods and Uses
|
AR051836A1
(es)
|
2004-11-30 |
2007-02-14 |
Centocor Inc |
Antagonistas de receptor 3 simil toll metodos y usos
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
US7700099B2
(en)
|
2005-02-14 |
2010-04-20 |
Merck & Co., Inc. |
Non-immunostimulatory antibody and compositions containing the same
|
TW200714289A
(en)
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
AR053579A1
(es)
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
JP2008538767A
(ja)
|
2005-04-22 |
2008-11-06 |
ジェネンテック・インコーポレーテッド |
Cd20抗体による認知症又はアルツハイマー病の治療方法
|
BRPI0611220A2
(pt)
|
2005-06-02 |
2010-08-24 |
Astrazeneca Ab |
anticorpos direcionados para cd20 e usos dos mesmos
|
MY169746A
(en)
|
2005-08-19 |
2019-05-14 |
Abbvie Inc |
Dual variable domain immunoglobulin and uses thereof
|
EP2500356A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
JP5686953B2
(ja)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用
|
US7790655B2
(en)
|
2005-10-14 |
2010-09-07 |
Medimmune, Llc |
Cell display of antibody libraries
|
KR20140091765A
(ko)
|
2006-01-12 |
2014-07-22 |
알렉시온 파마슈티칼스, 인코포레이티드 |
Ox-2/cd200에 대한 항체 및 이들의 용도
|
EP1820513A1
(en)
|
2006-02-15 |
2007-08-22 |
Trion Pharma Gmbh |
Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
|
KR20140057635A
(ko)
|
2006-03-15 |
2014-05-13 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
|
CA2644663A1
(en)
|
2006-03-23 |
2007-09-27 |
Kirin Pharma Kabushiki Kaisha |
Agonist antibody to human thrombopoietin receptor
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
CN101802015B
(zh)
|
2007-03-29 |
2015-05-06 |
根马布股份公司 |
双特异性抗体及其制造方法
|
US20100183615A1
(en)
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
ES2695047T3
(es)
|
2007-04-03 |
2018-12-28 |
Amgen Research (Munich) Gmbh |
Dominio de unión específico entre especies
|
WO2008143954A2
(en)
|
2007-05-14 |
2008-11-27 |
Biogen Idec Ma Inc. |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
JP5577243B2
(ja)
|
2007-05-30 |
2014-08-20 |
ポステク アカデミー−インダストリー ファウンデイション |
免疫グロブリン融合タンパク質
|
US20100325744A1
(en)
|
2007-05-31 |
2010-12-23 |
Genmab A/S |
Non-glycosylated recombinant monovalent antibodies
|
CA2688275A1
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Stable igg4 antibodies
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
AU2008282152B2
(en)
|
2007-07-31 |
2013-12-19 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human CD20 and method of using thereof
|
EP2572729A3
(en)
|
2007-08-10 |
2013-06-05 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
AU2008304756B8
(en)
|
2007-09-26 |
2015-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-IL-6 receptor antibody
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
CA2714296A1
(en)
|
2008-02-20 |
2009-08-27 |
G2 Inflammation Pty Ltd |
Humanized anti-c5ar antibodies
|
AU2009313389A1
(en)
|
2008-11-06 |
2010-05-14 |
Alexion Pharmaceuticals, Inc. |
Engineered antibodies with reduced immunogenicity and methods of making
|
PL2344539T3
(pl)
|
2008-11-07 |
2015-07-31 |
Amgen Res Munich Gmbh |
Leczenie pediatrycznej ostrej białaczki limfoblastycznej
|
AR074438A1
(es)
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
|
EP2373687B1
(en)
|
2008-12-03 |
2016-10-26 |
Genmab A/S |
Igg4 antibody variants having modifications in the constant region
|
CN102369291A
(zh)
|
2009-01-23 |
2012-03-07 |
比奥根艾迪克Ma公司 |
效应子功能降低的稳定Fc多肽及使用方法
|
TWI682995B
(zh)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
抗體恆定區域改變體
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
KR102010827B1
(ko)
|
2009-06-26 |
2019-08-14 |
리제너론 파마슈티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
AU2010324684B2
(en)
|
2009-11-30 |
2015-09-03 |
Janssen Biotech, Inc. |
Antibody Fc mutants with ablated effector functions
|
WO2011090762A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Heterodimer binding proteins and uses thereof
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
ES2603559T5
(es)
|
2010-02-08 |
2021-02-22 |
Regeneron Pharma |
Cadena ligera común de ratón
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス,インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
SG10201800757TA
(en)
*
|
2010-04-20 |
2018-02-27 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
SG185107A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Antibodies having reduced immunogenicity in a human
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
ES2618586T3
(es)
|
2010-09-16 |
2017-06-21 |
Baliopharm Ag |
Anticuerpo anti-huTNFR1
|
KR102244173B1
(ko)
|
2010-11-30 |
2021-04-26 |
추가이 세이야쿠 가부시키가이샤 |
세포상해 유도 치료제
|
HUE033205T2
(en)
|
2010-12-23 |
2017-11-28 |
Janssen Biotech Inc |
Active, protease-resistant antibody-FC mutant
|
WO2012109285A2
(en)
|
2011-02-08 |
2012-08-16 |
Medimmune, Llc |
Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
|
WO2012130831A1
(en)
|
2011-03-29 |
2012-10-04 |
Roche Glycart Ag |
Antibody fc variants
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
US20140370012A1
(en)
|
2012-01-27 |
2014-12-18 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
KR20150023535A
(ko)
|
2012-06-05 |
2015-03-05 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법
|
AU2013289883B2
(en)
|
2012-07-13 |
2018-11-01 |
Zymeworks Bc Inc. |
Bispecific asymmetric heterodimers comprising anti-CD3 constructs
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CA2889681C
(en)
|
2012-09-27 |
2023-04-11 |
Merus B.V. |
Bispecific igg antibodies as t cell engagers
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
US10087250B2
(en)
|
2012-10-08 |
2018-10-02 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
TWI682941B
(zh)
|
2013-02-01 |
2020-01-21 |
美商再生元醫藥公司 |
含嵌合恆定區之抗體
|
WO2015001085A1
(en)
|
2013-07-05 |
2015-01-08 |
Genmab B.V. |
Humanized or chimeric cd3 antibodies
|
CA2917886A1
(en)
|
2013-07-12 |
2015-01-15 |
Zymeworks Inc. |
Bispecific cd3 and cd19 antigen binding constructs
|
PE20210107A1
(es)
*
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
MX2016008098A
(es)
|
2013-12-20 |
2017-01-11 |
Hoffmann La Roche |
Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI701042B
(zh)
*
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
MX2017006312A
(es)
|
2014-11-17 |
2017-08-21 |
Regeneron Pharma |
Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
|
EP3277725B1
(en)
|
2015-03-30 |
2020-11-25 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
GB201506407D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
HRP20220133T8
(hr)
|
2015-09-23 |
2022-05-13 |
Regeneron Pharmaceuticals, Inc. |
Optimizirana anti-cd3 bispecifična antitijela i njihove upotrebe
|
US20170174781A1
(en)
|
2015-12-22 |
2017-06-22 |
Regeneron Pharmaceuticals, Inc. |
Bispecific Anti-CD20/Anti-CD3 Antibodies to Treat Acute Lymphoblastic Leukemia
|